Investing.com - United Therapeutics (NASDAQ: UTHR) reported second quarter EPS of $5.85, $0.63 worse than the analyst estimate of $6.48. Revenue for the quarter came in at $714.9M versus the consensus estimate of $689.93M.
United Therapeutics's stock price closed at $337.54. It is up 28.64% in the last 3 months and up 40.57% in the last 12 months.
United Therapeutics saw 3 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See United Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, United Therapeutics's Financial Health score is "excellent performance".
Check out United Therapeutics's recent earnings performance, and United Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in UTHR right now?
With UTHR making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed UTHR alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including UTHR, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is UTHR poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now